Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes
At the European Society for Medical Oncology Congress 2022, Dr. Naoto Ueno presented patient-reported quality-of-life outcomes from the DESTINY-Breast04 study, which found that compared to doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
Listen to the episode to her Dr. Ueno explain:
Create your
podcast in
minutes
It is Free